---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000067"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:51:09.618973+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ligand Q2 revenue rises 57% to $41.5M; GAAP net loss $51.9M on $33.8M Primrose Bio writedown

## Summary
- Total revenue $41.5M (+57% YoY); royalties $23.2M (+11%); Captisol $7.5M (+44%).
- GAAP net loss from continuing ops $51.9M ($2.88/sh) vs income $2.3M ($0.13) YoY; adjusted net income $25.8M ($1.40).
- Core adjusted net income $25.8M vs $11.7M YoY, excluding Viking stock sales and non-cash impairments.
- 2024 guidance reaffirmed: royalties $100-105M, total revenue $140-157M, core adj. EPS $5.00-$5.50.
- Completed $100M APEIRON Biologics acquisition (July 8); credit facility expanded to $125M.

## SEC filing metadata
- accession: 0000886163-24-000067
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000067/0000886163-24-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000067/lgnd-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000067
- JSON: https://secwatch.observer/filing/0000886163-24-000067.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.